Oxipit
Oxipit develops CE-certified AI medical imaging software for chest X-ray, chest CT, and musculoskeletal workflows, including the world's first CE Class IIb-certified autonomous chest X-ray reporting AI. Now part of Sectra after April 2026 acquisition.
- Company typePrivate
- Founded2017
- HeadquartersVilnius, Lithuania
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Oxipit does
Oxipit is a Vilnius, Lithuania-based medical imaging AI company founded in 2017 that develops CE-certified deep learning software for radiology workflows. Its portfolio spans three suites: the CXR Suite (chest X-ray), CT Suite, and MSK Suite, covering detection of 75+ chest X-ray findings, chest CT analysis for pulmonary embolism and lung lesions, and musculoskeletal X-ray fracture detection. The company's flagship product, ChestLink, is the world's first and only CE Class IIb-certified autonomous AI for healthy chest X-ray reporting, operating with 99.9% sensitivity to remove normal studies from radiologist worklists without human review. Complementary products include ChestEye CAD with triage, CT Eye, MSK Eye, and an NLP-based quality assurance tool that cross-references radiologist reports with AI findings to detect missed pathology.
The company generates revenue primarily through enterprise software licenses and subscriptions sold to hospitals, diagnostic imaging centers, public health clinics, and radiology service providers, distributed through direct enterprise sales supplemented by AI marketplaces (deepcOS, CARPL, Blackford) and regional distributors in Africa and Latin America. Oxipit holds CE, ANVISA (Brazil), and TGA (Australia) certifications, with deployments in 30+ countries and over 1.5 million cases processed in 2024, nearly 3x the 2023 volume. In April 2026, Oxipit was acquired by Swedish medical imaging IT company Sectra, becoming a dedicated AI development center within Sectra's Imaging IT Solutions division with access to Sectra's enterprise imaging customer base across 19 countries.
Oxipit firmographics
Firmographics- Name
- Oxipit
- Legal name
- Oxipit, UAB
- Website
- https://oxipit.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Oxipit develops CE-certified AI medical imaging software for chest X-ray, chest CT, and musculoskeletal workflows, including the world's first CE Class IIb-certified autonomous chest X-ray reporting AI. Now part of Sectra after April 2026 acquisition.
- Ownership category
- akta.pro rank
Oxipit industry classification
Industry- Product category
- Radiology AI Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
- akta.pro secondary industries
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Quality, Peer Review & Compliance Tools (MQSA/ACR/QA) (HLACALAL), Radiology Reporting, Dictation & Structured Reporting (HLACALAF), Medical Imaging AI (HDAAAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Oxipit is headquartered
LocationHeadquarters
- HQ city
- Vilnius
- HQ country
- Lithuania
- HQ region
- Europe
Offices1 record
Markets served
Oxipit business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- AI Medical Imaging Software Licenses: Oxipit generates revenue primarily through licensing its CE-certified medical imaging AI software (ChestLink, ChestEye, CT Eye, MSK Eye) to healthcare providers. Sales are structured as enterprise subscriptions or usage-based licenses, typically contracted through the company's own sales team or channel partners. Following acquisition by Sectra in April 2026, Oxipit operates as a dedicated AI development center within Sectra's Imaging IT Solutions operating area, with revenue flowing through Sectra's commercial infrastructure.
- Platform Marketplace Distribution: Oxipit generates revenue through marketplace and platform partnerships including deepcOS, CARPL, and Blackford. These partners distribute Oxipit solutions to their customer bases, with revenue shared through platform fees or per-study usage arrangements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing — pricing not publicly disclosed |
Go-to-market motion3 records
Distribution channels9 records
Marketing channels6 records
Oxipit product offering
Product offeringCore offering
Oxipit develops CE-certified AI software for radiology, offering autonomous chest X-ray reporting (ChestLink), computer-aided detection of 75+ radiological findings (ChestEye), real-time quality assurance (ChestEye Quality), chest CT analysis (CT Eye), and musculoskeletal X-ray analysis (MSK Eye). Solutions integrate directly into existing PACS/RIS environments of hospitals, radiology departments, and diagnostic imaging networks to automate routine reporting, prioritize urgent cases, and flag missed findings. The company sells through direct enterprise sales, AI marketplaces, and regional distributors, and operates as a dedicated AI development center within Sectra following its April 2026 acquisition.
Product overview
Oxipit offers three comprehensive AI suites covering chest X-ray, chest CT, and musculoskeletal imaging. The CXR Suite is the flagship portfolio combining three modules: ChestLink (world's first CE Class IIb certified autonomous AI for normal chest X-ray reporting with 99.9% sensitivity), ChestEye (CAD detecting 75 radiological findings with triage), and ChestEye Quality (real-time QA using NLP to detect missed findings). The CT Suite and MSK Suite extend this workflow-integrated AI approach into chest CT and musculoskeletal imaging respectively. All solutions are designed to integrate directly into existing PACS environments and support radiologists from study arrival through final report.
Differentiator
Problem solved
Functional benefit
Brands
- CXR Suite: AI suite for chest X-ray workflows including ChestLink autonomous AI, ChestEye CAD, and Quality assurance tools supporting 75 findings.
- CT Suite
- MSK Suite
- ChestEye
- ChestLink
Products and services
- CXR Suite Comprehensive chest X-ray AI suite combining ChestLink (autonomous reporting), ChestEye (CAD for 75 findings detection), and ChestEye Quality (real-time QA). Offers four workflow tiers from basic decision support to full autonomy for normal chest X-rays. Designed for hospitals, radiology departments, and diagnostic imaging centers.
- ChestLink World's first and only CE Class IIb certified autonomous AI for healthy chest X-ray reporting. Automatically identifies high-confidence normal examinations with 99.9% sensitivity and generates final reports without radiologist involvement, removing them from the radiologist worklist. Can automate up to 40% of chest X-ray workflow in general hospital settings and up to 80% in preventive health check settings.
- ChestEye AI CAD application that detects 75 common radiological findings in chest X-rays with an average AUC of 93%, including localization of suspicious areas and preliminary reporting. Includes a triage feature to prioritize time-sensitive cases. Targets hospitals and radiology departments seeking AI-assisted detection.
- ChestEye Quality AI-powered second-reader quality assurance tool that analyzes medical images and radiologist reports to prevent diagnostic errors. Uses NLP to cross-reference radiologist findings with AI-identified findings, alerting radiologists to missed findings in near-real time. Works with chest X-ray, MSK X-ray, mammography, and CT images.
- CT Suite Chest CT AI suite powered by CT Eye for detection, prioritization, and quality assurance. Assists radiologists in identifying pulmonary embolism, lung lesions, and lung consolidation in adult chest CT studies, with study prioritization and automated post-report quality checks. Designed for hospitals and radiology departments handling chest CT workflows.
- CT Eye CE-certified AI tool for chest CT imaging that supports radiologists in detecting pulmonary embolism, lung lesions, and lung consolidation. Provides study prioritization and automated post-report quality checks using NLP to compare AI findings with radiologist reports.
- MSK Suite Musculoskeletal X-ray AI suite powered by MSK Eye for fracture detection and quality assurance. Supports radiologists in identifying fractures, arthritis, osteoporosis, bone lesions, and other skeletal abnormalities across high-volume musculoskeletal imaging workflows.
- MSK Eye CE-certified AI tool for high-volume musculoskeletal X-ray reporting supporting findings such as fractures, dislocations, degenerative changes, arthritis, osteoporosis, bone lesions, and post-surgical findings. Includes triage prioritization and automated post-report quality checks.
Quantifiable outcome
- Automates up to 40% of chest X-ray reporting workflow in general hospitals; up to 80% in preventive health check settings
- +8 more outcomes
Companies that use Oxipit
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
Oxipit technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability7 records
Feature7 records
Oxipit partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered flagship, core and minor.
- SectraflagshipSwedish medical imaging IT company Sectra completed the acquisition of Oxipit in April 2026 (agreement announced March 5, 2026). Oxipit operates as a dedicated AI development center within Sectra's Imaging IT Solutions operating area. Sectra gains ownership of ChestLink (first CE Class IIB-certified autonomous chest X-ray AI), CT Eye, and MSK Eye. The acquisition strengthens Sectra's vendor-neutral AI marketplace and broadens its AI portfolio for diagnostic imaging. Sectra paid upfront cash consideration plus contingent consideration tied to commercial and regulatory milestones.
- German Medical InstitutecoreThe German Medical Institute in Cyprus selected Oxipit as its chest X-ray AI partner following a structured clinical evaluation of three leading vendors across 700+ real-world cases. Oxipit CXR Suite was chosen for pathology detection (CAD), smart triage, and semi-autonomous pre-populated reports, integrated via Newton's Tree PACS platform.
- Diagnostikum GroupcoreOne of Austria's largest private radiology providers (275,000+ patients annually) selected Oxipit CXR Suite after rigorous multi-vendor evaluation on its own retrospective dataset. Deployment via deepc integration platform. Diagnostikum noted Oxipit's strongest overall performance for their outpatient setting where the majority of exams are normal.
- Vestre Viken Health TrustcoreNorway's first pilot project for AI-powered thoracic X-ray imaging, led by Vestre Viken as part of a national AI procurement coordinated with Sykehuspartner and other regional health authorities. The pilot evaluates ChestLink in supervised mode with the goal of advancing toward autonomous clinical use. Vestre Viken represents a structured, multidisciplinary approach to AI implementation in clinical practice.
- UnilabsflagshipEuropean diagnostic services provider Unilabs selected Oxipit to deploy ChestLink and ChestEye throughout its European network following a comprehensive international evaluation process. Initial rollout starts in Portugal with option to extend across all Unilabs operations in Europe. Oxipit's AI streamlines chest X-ray reporting through automated triage and second-reading capabilities.
- deepccorePartnership integrates Oxipit's ChestLink, ChestEye, and ChestEye Quality into the deepcOS radiology AI platform. Healthcare institutions access Oxipit solutions through a single contract, billing, service, and support framework with full data protection and cybersecurity compliance.
- FIDI (Fundação Instituto de Pesquisa e Estudo de Diagnóstico por Imagem)flagshipFIDI, one of Latin America's largest radiology service providers (400,000+ studies/month across 90+ sites in Brazil), deployed Oxipit's chest X-ray AI in emergency departments via the CARPL platform integrated with Philips Vue PACS. AI-generated annotations appear directly on images, supporting ER physicians who lack real-time radiologist access. Reduced turnaround times from 1 hour to 5 minutes at some sites.
- BlackfordcoreBlackford, a strategic radiology AI platform with 100+ applications, integrates Oxipit's Quality application into its enterprise AI platform. Provides radiologists with an always-on AI second reader that flags potential missed findings by cross-referencing radiologist reports with AI image analysis.
- CARPLcoreCARPL platform, the world's only US FDA-cleared and CE-marked vendor-neutral AI platform, makes Oxipit's full product portfolio available to healthcare institutions globally. CARPL provides single-user interface, single data channel, and single procurement channel for testing, deployment, and monitoring of Oxipit AI in clinical workflows.
- AstraZenecaminorOxipit and AstraZeneca conducted a joint pilot study deploying ChestEye Quality AI for improved pulmonary nodule detection in two major primary care centers in Lithuania. Analysis of nearly 50,000 chest X-ray images in 2021 detected 82 additional clinically relevant nodule findings, potentially identifying additional early instances of lung cancer.
- ParasmedminorNairobi-based Parasmed, founded by a senior radiologist from Oulu University Hospital (Finland), distributes Oxipit CXR AI products across Eastern Africa. Before commercial deployment, Parasmed partners with local high-level medical institutions to evaluate software performance using real-world clinical data, demonstrating AI workflow to local institutions.
- Teleradiología de ColombiaminorLeading diagnostic imaging services provider in Colombia rolling out Oxipit AI solutions across its network, marking the first Oxipit deployment in Colombia with more announcements expected in Latin America.
- Healthcare KonnectcoreSwiss medical distribution company Healthcare Konnect distributes Oxipit's ChestEye AI imaging suite to healthcare institutions in Nigeria. Partnership aims to improve detection of 75 pathologies including tuberculosis in one of Africa's largest markets, addressing severe radiologist shortages (only ~400 specialists for the entire population).
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Oxipit competitors and assessment
Company assessmentDirect peers
- Qure.ai: Qure.ai is a leading AI radiology company with chest X-ray and head CT solutions (qXR, qER). It competes directly with Oxipit in autonomous and CAD chest X-ray AI, with similar target customers and global deployments.
- Lunit: Lunit develops AI for chest X-ray (Lunit INSIGHT CXR) and mammography, with FDA-cleared and CE-marked products. Directly comparable to Oxipit's CXR Suite in terms of modality, customer base, and go-to-market.
- Aidoc: Aidoc provides AI-driven triage and detection across CT and X-ray modalities. Overlaps with Oxipit's CT Eye and triage features, serving similar hospital and radiology department customers.
- Annalise.ai: Annalise.ai offers a comprehensive AI platform detecting 130+ findings on chest X-rays. Directly competes with Oxipit's ChestEye (75 findings) and targets similar radiology workflows globally.
- VUNO: VUNO develops AI medical imaging solutions including chest X-ray (VUNO Med-Chest X-ray) and CT. Comparable to Oxipit's portfolio in modality coverage and global commercial expansion in Asia and beyond.
- Delft Imaging: Delft Imaging develops AI for chest X-ray screening, particularly for tuberculosis. Comparable to Oxipit's emerging-market deployments (Nigeria, Eastern Africa) addressing similar radiologist-shortage problems.
Broad incumbents
- Siemens Healthineers (AI Radiology): Siemens Healthineers offers AI-Rad Companion and other radiology AI embedded within its enterprise imaging solutions. Represents a broad incumbent competitor that bundles AI with PACS, similar to how Sectra now bundles Oxipit.
- Philips (AI Imaging): Philips integrates AI imaging applications within its Vue PACS and enterprise imaging portfolio (e.g., Philips Algorithm Marketplace). Competes indirectly via platform partnerships where Oxipit is also deployed (e.g., FIDI/Philips Vue PACS).
Others
- Blackford: Blackford operates a vendor-neutral enterprise AI platform for radiology with 100+ apps. It is both a distribution partner for Oxipit's Quality application and an indirect competitor via other AI offerings on its platform.
Emerging players
- contextflow: contextflow offers AI for CT imaging (SEARCH Lung CT). Already a partnership collaborator with Oxipit at Leiden UMC for combined CT quality assurance, addressing similar clinical use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Oxipit social profiles
Digital presenceOxipit compliance and trust
Trust signalCompliance8 records
Oxipit financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oxipit leadership team
Management profileNumber of profiles
Profiles11 records
Oxipit funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oxipit M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oxipit
What does Oxipit do?
Oxipit develops CE-certified AI software for radiology, offering autonomous chest X-ray reporting (ChestLink), computer-aided detection of 75+ radiological findings (ChestEye), real-time quality assurance (ChestEye Quality), chest CT analysis (CT Eye), and musculoskeletal X-ray analysis (MSK Eye). Solutions integrate directly into existing PACS/RIS environments of hospitals, radiology departments, and diagnostic imaging networks to automate routine reporting, prioritize urgent cases, and flag missed findings. The company sells through direct enterprise sales, AI marketplaces, and regional distributors, and operates as a dedicated AI development center within Sectra following its April 2026 acquisition.
Is Oxipit a public or private company?
Oxipit is a private company. It is classified as corporate owned and is currently acquired.
When was Oxipit founded?
Oxipit was founded in 2017. It employs 11 to 50 people.
Where is Oxipit based?
Oxipit is headquartered in Vilnius, Lithuania, in the Europe region.
How does Oxipit make money?
Two revenue lines are on record. AI Medical Imaging Software Licenses are the primary driver. The others are platform Marketplace Distribution.
Who are Oxipit's main competitors?
Direct peers on record are Qure.ai, Lunit, Aidoc, Annalise.ai, VUNO and Delft Imaging. Broad incumbents are Siemens Healthineers (AI Radiology) and Philips (AI Imaging). Blackford is listed as an others. contextflow is listed as an emerging player.
Does Oxipit have an API?
No public API is recorded for Oxipit.
What industry is Oxipit in?
Oxipit's product category is Radiology AI Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 5132 and its SIC code is 7372.